查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193319

關節痛注射劑市場：按註射類型、關節、分銷渠道分類：2021-2031 年全球機遇分析和行業預測

Joint Pain Injections Market By Injection Type, By Joint Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 310 Pages | 商品交期: 2-3個工作天內

價格

全球關節痛注射劑市場預計2021年將達到62.7191億美元，2031年將達到131.7631億美元，2022年至2031年復合年增長率為7.7%。 .

關節疼痛注射是指將藥物直接應用於受損關節組織的非手術程序。 關節痛被定義為與各種原因相關的關節不適，例如關節炎或其類型、關節先前受傷、肌肉過度使用、抑鬱、焦慮、壓力和肥胖。 此外，白細胞介素抑製劑是最常見的注射劑之一，它結合了麻醉劑和皮質類固醇來緩解關節疼痛和炎症。

根據關節炎基金會的數據，截至 2022 年，將有大約 6000 萬成年人被診斷患有關節炎，四分之一的成年人將患有其中一種關節炎。據說有 由此可見，由於久坐不動的生活方式、肥胖率上升、運動損傷、壓力等原因，所有年齡段的關節炎患病率不斷上升，很可能導致關節痛針劑銷量的大規模增長。

此外，由於製藥公司引入尖端治療技術、患者對精確治療選擇的需求增加以及新興經濟體確保高收入，預計關節痛注射劑市場將增長。。

關節炎基金會表示，影響 16 歲以下兒童的炎症性疾病稱為青少年關節炎，影響美國近 300,000 名兒童和青少年。澳大利亞政府已啟動“國家關節炎戰略行動計劃”，該計劃旨在指導國家努力解決關節炎的負擔。 因此，政府的進一步努力和資金將促進市場的增長。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析
  • 專利情況

第 4 章關節痛注射市場：按註射類型

  • 概覽
    • 市場規模和預測
  • 白細胞介素抑製劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 透明質酸注射液
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章關節疼痛注射市場：按關節分類

  • 概覽
    • 市場規模和預測
  • 膝關節和踝關節
    • 主要市場趨勢、增長因素和機遇
    • 各地區的市場規模和預測
    • 市場分析：按國家/地區分類
  • 髖關節
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 肩/肘關節
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 脊柱小關節
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章關節疼痛注射劑市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
    • 醫院藥房關節痛注射劑市場，按類型
      • 公立醫院藥房市場規模和預測：按地區
      • 私立醫院藥房市場規模趨勢和預測：按地區
  • 藥店和零售藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 在線提供商
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 7 章關節疼痛注射市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按註射類型
    • 北美市場規模和預測：按聯合
    • 北美市場規模和預測：按分銷渠道
      • 北美醫院藥房關節痛注射劑市場：按類型分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按註入類型
    • 歐洲市場規模和預測：按聯合
    • 歐洲市場規模和預測：按分銷渠道
      • 歐洲醫院藥房的關節痛注射劑市場：按類型分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和預測：按註射類型分類
    • 亞太地區的市場規模和預測：按聯合
    • 亞太市場規模和預測：按分銷渠道
      • 亞太地區醫院藥房關節痛注射劑市場，按類型
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按註入類型
    • LAMEA 市場規模和預測：按聯合
    • LAMEA 市場規模和預測：按分銷渠道
      • LAMEA 醫院藥房關節痛注射劑市場：按類型分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第八章公司情況

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第九章公司簡介

  • Abbvie Inc
  • Anika Therapeutics
  • Bioventus
  • Eli Lilly and Company
  • Ferring Pharmaceuticals Inc.
  • PACIRA BIOSCIENCES（Flexion Therapeutics, Inc.）
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals
  • Zimmer Biomet
Product Code: A31459

The global joint pain injections market was valued at $6,271.91 million in 2021, and is projected to reach $13,176.31 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.

Joint pain injections refer to the non-surgical procedures that involves application of the medication directly to damage joint tissue. Joint pain is defined as the discomfort caused into the joints which is associated with the various reasons including the arthritis and its different kinds, the previous injuries to a joint, overuse of the muscle, depression, anxiety, stress, and obesity. Furthermore, interleukin inhibitors are one of the most common types of therapeutic injections that include an anesthetic agent combined with a corticosteroid to relieve joint pain and inflammation.

According to the Arthritis Foundation, as of the numbers generated in 2022 there are about 60 million adults who have been diagnosed with arthritis and 1 in 4 adults have one of these types of arthritis. This rise in incidence of arthritis among all age groups owing to a sedentary lifestyle, rise in obesity, injuries due to physical activities and stress, will lead to the sales of the joint pain injection on a large scale.

Furthermore, the joint pain injections market is anticipated to grow by the introduction of numerous cutting-edge treatment technologies by the pharmaceutical companies, an increase in the demand for accurate treatment options by the patients, and the availability of high income in the developed economies.

Arthritis Foundation also states that, the inflammatory and rheumatic diseases that develops in children under the age of 16 is known to be juvenile arthritis, which affects nearly 300,000 kids and teens in the U.S. However, the government of Australia has published 'The National Strategic Action Plan for Arthritis' that aims to guide national efforts to address the burden of arthritis. Thus, such more initiatives and funding provided by the government will boost the growth of the market.

In addition, the rise in investment for research and development of the advanced and precise treatment options by public and private players in the market with an aim to improve health care infrastructure, due to the rise in the prevalence of the arthritis, along with rise in the obesity and geriatric patients are the key factors for the expansion of the joint pain injections market. For instance, the U.S. FDA approval for the second indication for Skyrizi (risankizumab-rzaa) to treat adults with active psoriatic arthritis that can be administered with a single injection four times a year.

However, the market is expected to be significantly constrained in the near future by factors such as lack of awareness about these injections in developing nations, their expensive price, and lack of reimbursement policies that effects the adoption of the products in the emerging countries. However, the key market players are developing more efficient treatment options which includes the single injection therapy and plasma matrix therapy, which will provide lucrative opportunities during the forecast period.

The joint pain injections market is segmented on the basis of injection type, by joint type, by distribution channel and region. By injection type, it is divided into interleukin inhibitors, hyaluronic acid injections and others. On the basis of joint type, the market is segmented into knee & ankle, hip joint, shoulder & elbow, facet joints of the spine and others. According to the distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies and online providers. Further, the hospital pharmacies segment is divided into public hospital pharmacies and private hospital pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in this report include Abbvie Inc., Anika Therapeutics Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pacira Biosciences (Flexion Therapeutics, Inc.), Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Zimmer Biomet and among others.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the joint pain injections market analysis from 2021 to 2031 to identify the prevailing joint pain injections market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the joint pain injections market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global joint pain injections market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Injection Type

  • Interleukin Inhibitors
  • Hyaluronic Acid Injections
  • Others

By Joint Type

  • Knee and Ankle
  • Hip Joint
  • Shoulder and Elbow
  • Facet Joints of the Spine
  • Others

By Distribution Channel

  • Hospital Pharmacies
    • Type
    • Public Hospital Pharmacies
    • Private Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Abbvie Inc
    • Anika Therapeutics
    • Bioventus
    • Eli Lilly and Company
    • Ferring Pharmaceuticals Inc.
    • PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
    • Pfizer Inc.
    • Sanofi S.A.
    • Teva Pharmaceuticals
    • Zimmer Biomet

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Interleukin Inhibitors
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Hyaluronic Acid Injections
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Knee and Ankle
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Hip Joint
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Shoulder and Elbow
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Facet Joints of the Spine
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country
  • 5.6 Others
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market analysis by country

CHAPTER 6: JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
    • 6.2.4 Hospital Pharmacies Joint Pain Injections Market by Type
      • 6.2.4.1 Public Hospital Pharmacies Market size and forecast, by region
      • 6.2.4.2 Private Hospital Pharmacies Market size and forecast, by region
  • 6.3 Drug Stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: JOINT PAIN INJECTIONS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Injection Type
    • 7.2.3 North America Market size and forecast, by Joint Type
    • 7.2.4 North America Market size and forecast, by Distribution Channel
      • 7.2.4.1 North America Hospital Pharmacies Joint Pain Injections Market by Type
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Injection Type
      • 7.2.5.1.2 Market size and forecast, by Joint Type
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Injection Type
      • 7.2.5.2.2 Market size and forecast, by Joint Type
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Injection Type
      • 7.2.5.3.2 Market size and forecast, by Joint Type
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Injection Type
    • 7.3.3 Europe Market size and forecast, by Joint Type
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
      • 7.3.4.1 Europe Hospital Pharmacies Joint Pain Injections Market by Type
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Injection Type
      • 7.3.5.1.2 Market size and forecast, by Joint Type
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Injection Type
      • 7.3.5.2.2 Market size and forecast, by Joint Type
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Injection Type
      • 7.3.5.3.2 Market size and forecast, by Joint Type
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Injection Type
      • 7.3.5.4.2 Market size and forecast, by Joint Type
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Injection Type
      • 7.3.5.5.2 Market size and forecast, by Joint Type
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Injection Type
      • 7.3.5.6.2 Market size and forecast, by Joint Type
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Injection Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Joint Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
      • 7.4.4.1 Asia-Pacific Hospital Pharmacies Joint Pain Injections Market by Type
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Injection Type
      • 7.4.5.1.2 Market size and forecast, by Joint Type
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Injection Type
      • 7.4.5.2.2 Market size and forecast, by Joint Type
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Injection Type
      • 7.4.5.3.2 Market size and forecast, by Joint Type
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Injection Type
      • 7.4.5.4.2 Market size and forecast, by Joint Type
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Injection Type
      • 7.4.5.5.2 Market size and forecast, by Joint Type
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Injection Type
      • 7.4.5.6.2 Market size and forecast, by Joint Type
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Injection Type
    • 7.5.3 LAMEA Market size and forecast, by Joint Type
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
      • 7.5.4.1 LAMEA Hospital Pharmacies Joint Pain Injections Market by Type
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Injection Type
      • 7.5.5.1.2 Market size and forecast, by Joint Type
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Injection Type
      • 7.5.5.2.2 Market size and forecast, by Joint Type
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Injection Type
      • 7.5.5.3.2 Market size and forecast, by Joint Type
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Injection Type
      • 7.5.5.4.2 Market size and forecast, by Joint Type
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Abbvie Inc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Anika Therapeutics
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bioventus
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Eli Lilly and Company
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Ferring Pharmaceuticals Inc.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Pfizer Inc.
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Sanofi S.A.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Teva Pharmaceuticals
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Zimmer Biomet
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 2. JOINT PAIN INJECTIONS MARKET, FOR INTERLEUKIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. JOINT PAIN INJECTIONS MARKET FOR INTERLEUKIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. JOINT PAIN INJECTIONS MARKET, FOR HYALURONIC ACID INJECTIONS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. JOINT PAIN INJECTIONS MARKET FOR HYALURONIC ACID INJECTIONS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. JOINT PAIN INJECTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. JOINT PAIN INJECTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. GLOBAL JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 9. JOINT PAIN INJECTIONS MARKET, FOR KNEE AND ANKLE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. JOINT PAIN INJECTIONS MARKET FOR KNEE AND ANKLE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. JOINT PAIN INJECTIONS MARKET, FOR HIP JOINT, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. JOINT PAIN INJECTIONS MARKET FOR HIP JOINT, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. JOINT PAIN INJECTIONS MARKET, FOR SHOULDER AND ELBOW, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. JOINT PAIN INJECTIONS MARKET FOR SHOULDER AND ELBOW, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. JOINT PAIN INJECTIONS MARKET, FOR FACET JOINTS OF THE SPINE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. JOINT PAIN INJECTIONS MARKET FOR FACET JOINTS OF THE SPINE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. JOINT PAIN INJECTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. JOINT PAIN INJECTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. GLOBAL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 20. JOINT PAIN INJECTIONS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. JOINT PAIN INJECTIONS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 22. GLOBAL HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 23. JOINT PAIN INJECTIONS MARKET, FOR PUBLIC HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. JOINT PAIN INJECTIONS MARKET, FOR PRIVATE HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. JOINT PAIN INJECTIONS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 26. JOINT PAIN INJECTIONS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 27. JOINT PAIN INJECTIONS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 28. JOINT PAIN INJECTIONS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 29. JOINT PAIN INJECTIONS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 31. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 32. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 33. NORTH AMERICA HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 34. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 35. U.S. JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 36. U.S. JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 37. U.S. JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 38. CANADA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 39. CANADA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 40. CANADA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 41. MEXICO JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 42. MEXICO JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 43. MEXICO JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 45. EUROPE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 46. EUROPE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. EUROPE HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. EUROPE JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 49. GERMANY JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 50. GERMANY JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 51. GERMANY JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 52. FRANCE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 53. FRANCE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 54. FRANCE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 55. UK JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 56. UK JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 57. UK JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 58. ITALY JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 59. ITALY JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 60. ITALY JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 61. SPAIN JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 62. SPAIN JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 63. SPAIN JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 64. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 65. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 66. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 68. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 69. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. ASIA-PACIFIC HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 71. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 72. JAPAN JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 73. JAPAN JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 74. JAPAN JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 75. CHINA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 76. CHINA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 77. CHINA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 80. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 81. INDIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 82. INDIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 83. INDIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 84. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 85. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 86. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 87. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 89. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 91. LAMEA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 92. LAMEA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 93. LAMEA HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 94. LAMEA JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 95. BRAZIL JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 96. BRAZIL JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 97. BRAZIL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 98. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 99. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 100. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 101. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 102. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 103. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 104. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
  • TABLE 105. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
  • TABLE 106. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 107.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 108.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 109.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 110.ABBVIE INC: NET SALES,
  • TABLE 111.ABBVIE INC: KEY STRATERGIES
  • TABLE 112.ANIKA THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 113.ANIKA THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 114.ANIKA THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 115.ANIKA THERAPEUTICS: NET SALES,
  • TABLE 116.ANIKA THERAPEUTICS: KEY STRATERGIES
  • TABLE 117.BIOVENTUS: COMPANY SNAPSHOT
  • TABLE 118.BIOVENTUS: OPERATING SEGMENTS
  • TABLE 119.BIOVENTUS: PRODUCT PORTFOLIO
  • TABLE 120.BIOVENTUS: NET SALES,
  • TABLE 121.BIOVENTUS: KEY STRATERGIES
  • TABLE 122.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 123.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 124.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 125.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 126.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 127.FERRING PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 128.FERRING PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 129.FERRING PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 130.FERRING PHARMACEUTICALS INC.: NET SALES,
  • TABLE 131.FERRING PHARMACEUTICALS INC.: KEY STRATERGIES
  • TABLE 132.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): COMPANY SNAPSHOT
  • TABLE 133.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): OPERATING SEGMENTS
  • TABLE 134.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): PRODUCT PORTFOLIO
  • TABLE 135.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): NET SALES,
  • TABLE 136.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): KEY STRATERGIES
  • TABLE 137.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 138.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 139.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 140.PFIZER INC.: NET SALES,
  • TABLE 141.PFIZER INC.: KEY STRATERGIES
  • TABLE 142.SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 143.SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 144.SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 145.SANOFI S.A.: NET SALES,
  • TABLE 146.SANOFI S.A.: KEY STRATERGIES
  • TABLE 147.TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 148.TEVA PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 149.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 150.TEVA PHARMACEUTICALS: NET SALES,
  • TABLE 151.TEVA PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 152.ZIMMER BIOMET: COMPANY SNAPSHOT
  • TABLE 153.ZIMMER BIOMET: OPERATING SEGMENTS
  • TABLE 154.ZIMMER BIOMET: PRODUCT PORTFOLIO
  • TABLE 155.ZIMMER BIOMET: NET SALES,
  • TABLE 156.ZIMMER BIOMET: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.JOINT PAIN INJECTIONS MARKET SEGMENTATION
  • FIGURE 2.JOINT PAIN INJECTIONS MARKET,2021-2031
  • FIGURE 3.JOINT PAIN INJECTIONS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.JOINT PAIN INJECTIONS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.JOINT PAIN INJECTIONS MARKET,BY INJECTION TYPE,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INTERLEUKIN INHIBITORS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HYALURONIC ACID INJECTIONS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 18.JOINT PAIN INJECTIONS MARKET,BY JOINT TYPE,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF KNEE AND ANKLE JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HIP JOINT JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SHOULDER AND ELBOW JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF FACET JOINTS OF THE SPINE JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 24.JOINT PAIN INJECTIONS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
  • FIGURE 28.JOINT PAIN INJECTIONS MARKET BY REGION,2021
  • FIGURE 29.U.S. JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 30.CANADA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 31.MEXICO JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 32.GERMANY JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 33.FRANCE JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 34.UK JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 35.ITALY JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 36.SPAIN JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 37.REST OF EUROPE JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 38.JAPAN JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 39.CHINA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 40.AUSTRALIA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 41.INDIA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 42.SOUTH KOREA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 44.BRAZIL JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 45.SAUDI ARABIA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 46.SOUTH AFRICA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 47.REST OF LAMEA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52.COMPETITIVE DASHBOARD
  • FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 54.ABBVIE INC.: NET SALES ,($MILLION)
  • FIGURE 55.ANIKA THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 56.BIOVENTUS.: NET SALES ,($MILLION)
  • FIGURE 57.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 58.FERRING PHARMACEUTICALS INC..: NET SALES ,($MILLION)
  • FIGURE 59.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.).: NET SALES ,($MILLION)
  • FIGURE 60.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 61.SANOFI S.A..: NET SALES ,($MILLION)
  • FIGURE 62.TEVA PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 63.ZIMMER BIOMET.: NET SALES ,($MILLION)